High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies

Chemotherapy

Volumn 56, Issue 2, 2010, Pages 108-111

  Kesterson, Joshua P ^a   Odunsi, Kunle ^a   Lele, Shashikant ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cardiotoxicity; Pegylated liposomal doxorubicin

Indexed keywords

DOXORUBICIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CARDIAC GATED IMAGING; CARDIOTOXICITY; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; GYNECOLOGIC CANCER; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UTERINE CERVIX CANCER; UTERINE TUBE TUMOR; VULVA CANCER;

ANTIBIOTICS, ANTINEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; GENITAL NEOPLASMS, FEMALE; HEART; HUMANS; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES;

EID: 77952263778     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000312644     Document Type: Article

References (20)

1. Swain SM, Whaley FS, Ewer MS: Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-2879.
2. al-Gharably NM, Osman AM, al-Shabanah OA, al-Bekairi AM, al-Harbi MM: Potentiation of doxorubicin cytotoxicity by the calcium channel blocker verapamil in Ehrlich ascites cells. Chemotherapy 1993; 39: 410-415.
3. al-Shabanah OA, Osman AM, al-Harbi MM, al-Gharably NM, al-Bekairi AM: Enhancement of doxorubicin-induced cytotoxicity by hyperthermia in Ehrlich ascites cells. Chemotherapy 1994; 40: 188-194.
4. Waterhouse DN, Tardi PG, Mayer LD, Bally MB: A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf 2001; 24: 903-920.
5. Campos SM, Penson RT, Mays AR, Berkowitz RS, Fuller AF, Goodman A, Matulonis UA, Muzikansky A, Seiden MV: The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 2001; 81: 206-212.
6. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, Sharpington T: Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18: 3093-3100.
7. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987-993.
8. Rose PG, Maxson JH, Fusco N, Mossbruger K, Rodriguez M: Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of singleagent dosages. Gynecol Oncol 2001; 82: 323-328.
9. Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M, Mc- Meekin DS, Monk BJ, Rose PG: Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol 2005; 96: 10-18.
10. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440-449.
11. Andreopoulou E, Gaiotti D, Kim E, Downey A, Mirchandani D, Hamilton A, Jacobs A, Curtin J, Muggia F: Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol 2007; 18: 716-721.
12. Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, Henderson R, Berry G, Gabizon A: Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m 2 . Ann Oncol 2000; 11: 1029-1033.
13. Uyar D, Kulp B, Peterson G, Zanotti K, Markman M, Belinson J: Cardiac safety profile of prolonged ( 6 6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies. Gynecol Oncol 2004; 94: 147-151.
14. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i-xii, 1-253.
15. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-3322.
16. Theodoulou M, Hudis C: Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer 2004; 100: 2052-2063.
17. Schwartz RG, McKenzie WB, Alexander J, Sager P, D'Souza A, Manatunga A, Schwartz PE, Berger HJ, Setaro J, Surkin L, et al: Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987; 82: 1109-1118.
18. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB: Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008; 26: 3777-3784.
19. Ng R, Better N, Green MD: Anticancer agents and cardiotoxicity. Semin Oncol 2006; 33: 2-14.
20. Urbanova D, Urban L, Danova K, Simkova I: Natriuretic peptides: biochemical markers of anthracycline cardiac toxicity? Oncol Res 2008; 17: 51-58.